Related Experiment Video
Updated: May 14, 2026

The Soft Agar Colony Formation Assay
Published on: October 27, 2014
Role of WNT7B-induced noncanonical pathway in advanced prostate cancer
Dali Zheng1, Keith F Decker, Tianhua Zhou
1Center for Pharmacogenomics, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Abstract:
Advanced prostate cancer is characterized by incurable castration-resistant progression and osteoblastic bone metastasis. While androgen deprivation therapy remains the primary treatment for advanced prostate cancer, resistance inevitably develops. Importantly, mounting evidence indicates that androgen receptor (AR) signaling continues to play a critical role in the growth of advanced prostate cancer despite androgen deprivation. While the mechanisms of aberrant AR activation in advanced prostate cancer have been extensively studied, the downstream AR target genes involved in the progression of castration resistance are largely unknown. Here, we identify WNT7B as a direct AR target gene highly expressed in castration-resistant prostate cancer (CRPC) cells. Our results show that expression of WNT7B is necessary for the growth of prostate cancer cells and that this effect is enhanced under androgen-deprived conditions. Further analyses reveal that WNT7B promotes androgen-independent growth of CRPC cells likely through the activation of protein kinase C isozymes. Our results also show that prostate cancer-produced WNT7B induces osteoblast differentiation in vitro through a direct cell-cell interaction, and that WNT7B is upregulated in human prostate cancer xenografts that cause an osteoblastic reaction when grown in bone. Taken together, these results suggest that AR-regulated WNT7B signaling is critical for the growth of CRPC and development of the osteoblastic bone response characteristic of advanced prostate cancer.
Insights
WNT7B is a key gene in advanced prostate cancer growth and bone metastasis. Targeting this androgen receptor-regulated pathway may offer new treatments for castration-resistant prostate cancer.
Area of Science:
- Oncology
- Molecular Biology
- Endocrinology
Background:
- Advanced prostate cancer often becomes castration-resistant, continuing to grow despite androgen deprivation therapy.
- Androgen receptor (AR) signaling remains crucial for advanced prostate cancer growth, even without androgens.
- Downstream AR target genes driving castration resistance are not well understood.
Purpose of the Study:
- To identify novel androgen receptor (AR) target genes involved in castration-resistant prostate cancer (CRPC) progression.
- To investigate the role of WNT7B in CRPC growth and osteoblastic bone metastasis.
Main Methods:
- Gene expression analysis in CRPC cells.
- Functional assays to assess WNT7B's role in cell growth under androgen-deprived conditions.
- In vitro studies on WNT7B-induced osteoblast differentiation.
- Analysis of WNT7B expression in prostate cancer xenografts.
Main Results:
- WNT7B was identified as a direct AR target gene highly expressed in CRPC cells.
- WNT7B expression is essential for prostate cancer cell growth, particularly under androgen deprivation.
- WNT7B promotes androgen-independent CRPC growth, potentially via protein kinase C activation.
- Prostate cancer-derived WNT7B induces osteoblast differentiation in vitro and is upregulated in bone metastatic xenografts.
Conclusions:
- AR-regulated WNT7B signaling is critical for CRPC growth.
- WNT7B plays a significant role in the development of osteoblastic bone responses in advanced prostate cancer.
- Targeting WNT7B may represent a therapeutic strategy for advanced prostate cancer with bone metastasis.
Related Concept Videos
Canonical Wnt Signaling Pathway
Canonical Wnt Signaling Pathway
Non-Canonical Wnt Signaling Pathways
Non-Canonical Wnt Signaling Pathways
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
